Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410299 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HSD17B10NR4A2 | |
| SCHEMBL29843346 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP3A4HSD17B10NR4A2 | |
| SCHEMBL2153752 | 0.76 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL29487594 | 0.76 | ALDH1A1 (0.54) | ALDH1A1TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL30366335 | 0.76 | CYP2A6 (0.54) | ALDH1A1TSHRHSD17B10CYP2A6HTT | |
| SCHEMBL5024019 | 0.76 | CYP2A6 (0.54) | ALDH1A1TSHRHSD17B10CYP2A6HTT | |
| SCHEMBL31179229 | 0.76 | CYP3A4 (0.54) | ALDH1A1TSHRCYP3A4HSD17B10NR4A2 | |
| SCHEMBL4083992 | 0.76 | CYP3A4 (0.54) | ALDH1A1TSHRCYP3A4HSD17B10NR4A2 | |
| SCHEMBL31157796 | 0.74 | ALDH1A1 (0.52) | ALDH1A1TSHRCYP3A4HSD17B10HPGD | |
| SCHEMBL5383334 | 0.74 | HPRT1 (0.54) | ALDH1A1TSHRCYP3A4HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790139-A | Method for synthesizing 2-chloro-4-fluorobenzoic acid by taking 2-chloro-4-amino bromobenzene as raw material | 江苏中旗科技股份有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-108530365-A | 1,4- naphthoquinones/anthraquinone imdazole derivatives and its preparation and use | 上海交通大学 | 2018-09-14 | — | — | CN | claimed |
| US-6590100-B2 | Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst | RHODIA CHIMIE (FR) | 2003-07-08 | — | — | US | claimed |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | SHASUN PHARMA SOLUTIONS, INC. | 2002-11-21 | — | — | US | claimed |
| US-20240174650-A1 | 8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LONGIVITRON (SUZHOU) BIOTECHNOLOGY CO., LTD (CN) | 2024-05-30 | — | — | US | disclosed |
| EP-4303219-A1 | 8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Longivitron (Suzhou) Biotechnology Co., Ltd (CN) | 2024-01-10 | — | — | EP | disclosed |
| CN-112334463-B | Compound and organic light emitting device comprising the same | 株式会社LG化学 | 2023-09-01 | — | — | CN | disclosed |
| CN-112939955-B | 8- (pyridine amide) substituted coumarin compound and preparation method and application thereof | 朗捷睿(苏州)生物科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022183963-A1 | 8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 朗捷睿(苏州)生物科技有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-112939955-A | 8- (pyridine amide) substituted coumarin compound and preparation method and application thereof | 朗捷睿(苏州)生物科技有限公司 | 2021-06-11 | — | — | CN | disclosed |
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | OSAKA UNIVERSITY (JP) | 2020-10-06 | — | — | US | disclosed |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | OSAKA UNIVERSITY (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-1689737-B1 | BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| CN-1878764-A | Beta-lactams for treatment of cns disorders | GLAXO GROUP LTD (GB) | 2006-12-13 | — | — | CN | disclosed |
| CN-1863784-A | 2-naphthylimino-1,3-thiazine derivative | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1689737-A1 | BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049600-A1 | BETA-LACTAMS FOR TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-6590100-B2 | Reacting an aromatic compound bearing a leaving group and an arylboronic acid and/or its derivatives in the presence of a base and an effective amount of a nickel catalyst | RHODIA CHIMIE (FR) | 2003-07-08 | — | — | US | disclosed |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | SHASUN PHARMA SOLUTIONS, INC. | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793584-B2 | Naphthobischalcogenadiazole derivative and production method therefor | CYP24A1, CYP26B1, CYP21A2 | ALDH1A1 600/4885TSHR 1397/4885CYP3A4 389/4885 |
| US-20190337966-A1 | NAPHTHOBISCHALCOGENADIAZOLE DERIVATIVE AND PRODUCTION METHOD THEREFOR | CYP24A1, CYP26B1, CYP21A2 | ALDH1A1 600/4885TSHR 1397/4885CYP3A4 389/4885 |
| US-20240174650-A1 | 8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SIRT2, SIRT1, SIRT7 | ALDH1A1 1100/4885TSHR 2996/4885CYP3A4 1635/4885 |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | ALDH1A1 1571/4885TSHR 440/4885CYP3A4 95/4885 |
| US-20020173652-A1 | Process for preparing a polyaromatic compound | PAH, ALK, ITPA | ALDH1A1 2981/4885TSHR 4264/4885CYP3A4 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.